Phaseline

Targets › ELANE

ELANE (Neutrophil elastase): drug programs, companies and trials

6 programs from 6 companies in 7 trials: 3 Phase 1, 2 Phase 2, 1 Phase 4, 1 Phase 3; Respiratory, Oncology, Gastroenterology; next expected readout Jul 2027.

Serine protease that modifies the functions of natural killer cells, monocytes and granulocytes. Shows microbicidal activity in neutrophils by mediating cleavage and degradation of bacterial proteins. (UniProt, P08246)

Open in Phaseline: the race on ELANE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CSL Behring.Alpha.1-Proteinase Inhibitor Human (CE1226)
Leukocyte elastase inhibitor
ELANEPhase 4Alpha1 Antitrypsin Deficiency; Eosinophilic EsophagitisSep 2033
Grifols Therapeutics.Alpha.1-Proteinase Inhibitor Human
Leukocyte elastase inhibitor
ELANEPhase 3Pulmonary Emphysema in Alpha-1 PI Deficiency–
Affiliated Hospital of Nantong UniversitySivelestat Sodium
Neutrophil elastase inhibitor
ELANEPhase 2Coronary Heart DiseaseJul 2027
National Cancer Institute (NCI)Alvelestat (MPH966)
Leukocyte elastase inhibitor
ELANEPhase 1Chronic Graft vs Host DiseaseDec 2027
Kyushu UniversitySivelestat sodium hydrate
Neutrophil elastase inhibitor
ELANEPhase 1Neuromyelitis Optica Spectrum Disorder AttackJan 2028
Onchilles PharmaN17350
Recombinant mutant porcine pancreatic elastase (PPE) targeting the neutrophil elastase (EL
ELANEPhase 1Neoplasms, Solid TumorJul 2028

Conditions

Neoplasms, Solid Tumor (1) Alpha1 Antitrypsin Deficiency (1) Eosinophilic Esophagitis (1) Coronary Heart Disease (1) Neuromyelitis Optica Spectrum Disorder Attack (1) Chronic Graft vs Host Disease (1) Pulmonary Emphysema in Alpha-1 PI Deficiency (1)

Modalities

protein or peptide (3), small molecule (3)

Companies

Onchilles Pharma (1) CSL Behring (1) Affiliated Hospital of Nantong University (1) Kyushu University (1) National Cancer Institute (NCI) (1) Grifols Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.